Jaguar Health Inc. [NASDAQ: JAGX] surged by $0.01 during the normal trading session on Monday and reaching a high of $0.3544 during the day while it closed the day at $0.33. The company report on July 5, 2022 that Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee to Assess Opportunities for Alliances, Mergers, and Acquisitions.
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Greg Divis departs from Jaguar’s Board of Directors; Experienced business development executive Rachel Zolot Schwartz chairs new committee.
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that it has appointed Anula Jayasuriya, M.D., Ph.D., M.B.A., to the company’s Board of Directors, effective July 1, 2022. Dr. Jayasuriya is a highly experienced healthcare private equity executive and venture capitalist with broad clinical, industry, entrepreneurial, and investment experience. Jaguar today also announced that it has established a Business Development Advisory Committee to identify and assess opportunities for potential alliances, mergers, and acquisitions.
Jaguar Health Inc. stock has also gained 6.32% of its value over the past 7 days. However, JAGX stock has declined by -33.06% in the 3 months of the year. Over the past six months meanwhile, it has lost -58.50% and lost -67.80% year-on date.
The market cap for JAGX stock reached $27.47 million, with 44.71 million shares outstanding. Compared to the average trading volume of 1.74M shares, JAGX reached a trading volume of 10600130 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Jaguar Health Inc. [JAGX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JAGX shares is $10.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JAGX stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Jaguar Health Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 07, 2021. While these analysts kept the previous recommendation, Rodman & Renshaw raised their target price to Buy. The new note on the price target was released on July 11, 2017, representing the official price target for Jaguar Health Inc. stock.
The Average True Range (ATR) for Jaguar Health Inc. is set at 0.02, with the Price to Sales ratio for JAGX stock in the period of the last 12 months amounting to 4.82. The Price to Book ratio for the last quarter was 1.86, with the Price to Cash per share for the same quarter was set at 0.21.
JAGX stock trade performance evaluation
Jaguar Health Inc. [JAGX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.32. With this latest performance, JAGX shares gained by 10.64% in over the last four-week period, additionally sinking by -58.50% over the last 6 months – not to mention a drop of -92.56% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JAGX stock in for the last two-week period is set at 53.70, with the RSI for the last a single of trading hit 59.80, and the three-weeks RSI is set at 48.91 for Jaguar Health Inc. [JAGX]. The present Moving Average for the last 50 days of trading for this stock 0.3373, while it was recorded at 0.3224 for the last single week of trading, and 0.8507 for the last 200 days.
Jaguar Health Inc. [JAGX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Jaguar Health Inc. [JAGX] shares currently have an operating margin of -939.05 and a Gross Margin at +46.18. Jaguar Health Inc.’s Net Margin is presently recorded at -1213.26.
Return on Equity for this stock declined to -365.08, with Return on Assets sitting at -109.45.
Jaguar Health Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.50.
Earnings per share (EPS) analysis for Jaguar Health Inc. [JAGX] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for JAGX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Jaguar Health Inc. go to 40.00%.
Jaguar Health Inc. [JAGX]: Insider Ownership positions
There are presently around $2 million, or 7.50% of JAGX stock, in the hands of institutional investors. The top three institutional holders of JAGX stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 1,522,997, which is approximately New of the company’s market cap and around 0.30% of the total institutional ownership; VANGUARD GROUP INC, holding 1,075,540 shares of the stock with an approximate value of $0.36 million in JAGX stocks shares; and BLACKROCK INC., currently with $0.26 million in JAGX stock with ownership of nearly -0.688% of the company’s market capitalization.
Positions in Jaguar Health Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 19 institutional holders increased their position in Jaguar Health Inc. [NASDAQ:JAGX] by around 2,489,271 shares. Additionally, 15 investors decreased positions by around 1,490,803 shares, while 5 investors held positions by with 1,590,886 shares. The mentioned changes placed institutional holdings at 5,570,960 shares, according to the latest SEC report filing. JAGX stock had 11 new institutional investments in for a total of 1,899,670 shares, while 6 institutional investors sold positions of 212,256 shares during the same period.